David Joske

4.6k total citations · 2 hit papers
45 papers, 2.6k citations indexed

About

David Joske is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, David Joske has authored 45 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 18 papers in Pathology and Forensic Medicine and 15 papers in Hematology. Recurrent topics in David Joske's work include Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Chronic Myeloid Leukemia Treatments (9 papers). David Joske is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Chronic Myeloid Leukemia Treatments (9 papers). David Joske collaborates with scholars based in Australia, United States and Switzerland. David Joske's co-authors include Andrew Grigg, John F. Seymour, H. Miles Prince, Susan Branford, Timothy P. Hughes, Kevin Lynch, Chris Arthur, Zbigniew Rudzki, Jeff Szer and Mark Kirschbaum and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

David Joske

45 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

2009 561 citations Richard Piekarz, Robin Frye et al. profile →
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

2003 561 citations Susan Branford, Zbigniew Rudzki et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Joske Australia	20	906	809	774	741	634	45	2.6k
Françoise Rigal‐Huguet France	25	1.3k 1.4×	837 1.0×	1.0k 1.3×	692 0.9×	869 1.4×	66	2.7k
Gandhi Damaj France	28	501 0.6×	698 0.9×	841 1.1×	329 0.4×	514 0.8×	125	2.3k
Norifumi Tsukamoto Japan	25	826 0.9×	561 0.7×	706 0.9×	381 0.5×	433 0.7×	139	2.1k
Monica Bocchia Italy	28	1.3k 1.4×	1.1k 1.3×	850 1.1×	560 0.8×	1.0k 1.6×	179	2.9k
Judit Demeter Hungary	18	426 0.5×	562 0.7×	553 0.7×	301 0.4×	413 0.7×	117	1.6k
Shin Fujisawa Japan	27	1.1k 1.2×	561 0.7×	410 0.5×	380 0.5×	572 0.9×	182	2.2k
G. Tertian France	17	578 0.6×	684 0.8×	522 0.7×	468 0.6×	364 0.6×	48	2.0k
Anna Porwit‐MacDonald Sweden	30	1.1k 1.3×	631 0.8×	938 1.2×	610 0.8×	604 1.0×	50	2.7k
Raymond E. Felgar United States	22	271 0.3×	536 0.7×	891 1.2×	240 0.3×	486 0.8×	38	2.8k
Jean‐Michel Cayuela France	33	2.1k 2.4×	837 1.0×	487 0.6×	1.0k 1.4×	784 1.2×	101	3.8k

Countries citing papers authored by David Joske

Since Specialization

Citations

This map shows the geographic impact of David Joske's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Joske with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Joske more than expected).

Fields of papers citing papers by David Joske

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Joske. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Joske. The network helps show where David Joske may publish in the future.

Co-authorship network of co-authors of David Joske

This figure shows the co-authorship network connecting the top 25 collaborators of David Joske. A scholar is included among the top collaborators of David Joske based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Joske. David Joske is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McCormack, Christopher, Jillian Wells, Belinda A. Campbell, et al.. (2020). Mycosis fungoides and Sézary syndrome: Australian clinical practice statement. Australasian Journal of Dermatology. 62(1). e8–e18. 8 indexed citations

Lasica, Masa, Abbey Willcox, Kate Burbury, et al.. (2019). The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leukemia & lymphoma. 60(7). 1796–1802. 15 indexed citations

Steiner, Raphaël, Chelsea C. Pinnix, Bouthaina S. Dabaja, et al.. (2019). An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. Cancer Medicine. 9(2). 663–670. 16 indexed citations

Selvey, Linda, Claudia Slimings, David Joske, & Thomas V. Riley. (2016). Clostridium difficile Infections amongst Patients with Haematological Malignancies: A Data Linkage Study. PLoS ONE. 11(6). e0157839–e0157839. 22 indexed citations

Cull, Gavin, et al.. (2016). Green tea polyphenol “epigallocatechin-3-gallate”, differentially induces apoptosis in CLL B-and T-Cells but not in healthy B-and T-Cells in a dose dependant manner. Leukemia Research. 51. 56–61. 15 indexed citations

Leeuwen, Marina T. van, Jennifer Turner, Michael O. Falster, et al.. (2013). Latitude gradients for lymphoid neoplasm subtypes in Australia support an association with ultraviolet radiation exposure. International Journal of Cancer. 133(4). 944–951. 32 indexed citations

Spagnolo, Dominic V., et al.. (2012). Cutaneous Intravascular Anaplastic Large T-Cell Lymphoma. American Journal of Dermatopathology. 34(8). e133–e138. 20 indexed citations

Ghassemifar, Reza, et al.. (2012). Differential expression of the Bcl-2 and Bax isoforms in CD19 positive B-lymphocytes isolated from patients diagnosed with chronic lymphocytic leukaemia. Pathology. 44(7). 632–637. 5 indexed citations

Piekarz, Richard, Robin Frye, H. Miles Prince, et al.. (2011). Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 117(22). 5827–5834. 359 indexed citations

10.

Pasqüini, Ricardo, Jörge E. Cortes, Hagop M. Kantarjian, et al.. (2011). Survey of the Frontline Treatment and Management of Chronic Myeloid Leukemia (CML) in a Real-Word Setting: The 3rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry). Blood. 118(21). 1695–1695. 3 indexed citations

11.

Baade, Peter D., et al.. (2010). Risk of second cancer after lymphohematopoietic neoplasm. International Journal of Cancer. 129(4). 910–919. 25 indexed citations

12.

Kargotich, Stephen, David Keast, Carmél Goodman, et al.. (2007). Monitoring 6 Weeks of Progressive Endurance Training with Plasma Glutamine. International Journal of Sports Medicine. 28(3). 211–216. 32 indexed citations

13.

Branford, Susan, Zbigniew Rudzki, Andrew Grigg, et al.. (2004). BCR-ABL Levels Continue To Decrease up to 42 Months after Commencement of Standard Dose Imatinib in Patients with Newly Diagnosed Chronic Phase CML Who Achieve a Major Molecular Response.. Blood. 104(11). 274–274. 10 indexed citations

14.

Branford, Susan, Zbigniew Rudzki, Ian Parkinson, et al.. (2003). Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 102(1). 276–283. 561 indexed citations breakdown →

15.

Branford, Susan, Zbigniew Rudzki, Andrew Harper, et al.. (2003). Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 17(12). 2401–2409. 118 indexed citations

16.

Moore, John J., Peter Brooks, Sam Milliken, et al.. (2002). A pilot randomized trial comparing CD34‐selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis & Rheumatism. 46(9). 2301–2309. 125 indexed citations

17.

Chapman, Caroline, et al.. (2002). Polymorphisms in the Interleukin 10 Gene Promoter are Associated with Susceptibility to Aggressive Non-Hodgkin's Lymphoma. Leukemia & lymphoma. 44(2). 251–255. 52 indexed citations

18.

Cohen, B J, Sally Beard, Wendy A. Knowles, et al.. (1997). Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion. 37(9). 947–952. 66 indexed citations

19.

Knecht, Hans, et al.. (1993). Expression of human recombination activating genes (RAG‐1 and RAG‐2) in angioimmunoblastic lymphadenopathy and anaplastic large cell lymphoma of T‐type. British Journal of Haematology. 83(4). 655–659. 4 indexed citations

20.

Knecht, Hans, Elias Bachmann, David Joske, et al.. (1993). Molecular analysis of the LMP (latent membrane protein) oncogene in Hodgkin's disease.. PubMed. 7(4). 580–5. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact